DNA mismatch repair gene mutations affect the body’s ability to correct errors that occur naturally during DNA copying, leading to increased mutation rates and potential health complications. Understanding when and how to test for these mutations can help individuals and families make informed decisions about their health care.

Introduction: Who Should Undergo Testing

Testing for DNA mismatch repair protein gene mutations is particularly important for individuals who have a personal or family history of certain cancers, especially colorectal cancer that develops at a younger age than usual. DNA mismatch repair, or MMR, is a biological system that acts like a quality control mechanism for your genetic material, fixing mistakes that happen when cells copy their DNA before dividing.^[1]

When the genes responsible for this repair system carry mutations, the body loses its ability to fix these copying errors effectively. This means mistakes accumulate over time, increasing the likelihood that cells will develop harmful changes that could lead to cancer. The condition caused by inherited defects in these repair genes is known as hereditary nonpolyposis colorectal cancer, and it significantly increases the risk of developing various types of cancer.^[2]

People who should consider diagnostic testing include those with multiple family members affected by colorectal, endometrial, or other related cancers, particularly if these cancers occurred before age 50. Additionally, individuals who have already been diagnosed with cancer may undergo testing to determine if their tumor shows signs of mismatch repair deficiency, as this information can guide treatment decisions. Those with unusual patterns of cancer in their families, such as multiple types of cancer in the same person or cancer affecting several generations, should also discuss testing with their healthcare provider.^[3]

Testing is also recommended for people whose family members have already been found to carry a mutation in one of the mismatch repair genes. In these cases, targeted testing can determine if other family members inherited the same genetic change. Early detection through diagnostic testing allows individuals to pursue enhanced screening protocols and preventive measures that may reduce cancer risk or detect cancer at more treatable stages.

Classic Diagnostic Methods

Diagnosing DNA mismatch repair protein gene mutations involves several complementary approaches that work together to provide a complete picture. The diagnostic process typically begins with an examination of tumor tissue in people who have already developed cancer, as this can reveal important clues about whether the mismatch repair system is functioning properly.^[8]

One of the most widely used initial screening methods is testing for microsatellite instability, abbreviated as MSI. Microsatellites are short, repetitive sequences of DNA scattered throughout the genome. When mismatch repair is not working correctly, errors in copying these repetitive regions accumulate, causing them to become unstable. During replication through these microsatellite areas, the DNA strand can slip, creating insertion or deletion errors that would normally be corrected by the MMR system. Since these errors escape repair when MMR is deficient, microsatellite instability becomes a hallmark feature that doctors can detect in laboratory tests.^[2]

Laboratory technicians analyze tumor tissue by comparing the length of specific microsatellite sequences in the cancer cells to those in normal cells from the same person. If many of these sequences show differences in length between the tumor and normal tissue, this indicates high microsatellite instability and suggests that mismatch repair is not functioning properly. This test has become a standard diagnostic marker because MMR-deficient cells consistently display this instability pattern.^[8]

Another crucial diagnostic technique is immunohistochemistry, which examines whether mismatch repair proteins are actually present in tumor cells. This laboratory method uses special stains that bind to specific MMR proteins, including MLH1, MSH2, MSH6, and PMS2. When examined under a microscope, normal cells show staining because the proteins are present, while cells lacking these proteins due to gene mutations do not stain. A loss of staining for one or more of these proteins indicates that the corresponding gene may be mutated or silenced, pointing to a mismatch repair deficiency.^[1]

The immunohistochemistry results help guide further testing by indicating which specific gene may be affected. For example, if a tumor shows loss of MLH1 staining but normal staining for the other proteins, this suggests that the MLH1 gene is involved. This information narrows down which genes should be examined more closely through genetic sequencing, making the diagnostic process more efficient and cost-effective.

Genetic testing through DNA sequencing provides definitive diagnosis by identifying the exact mutation in mismatch repair genes. This testing can be performed on tumor tissue to find mutations that developed in the cancer itself, or on blood or saliva samples to detect inherited mutations present in all cells of the body. Sequencing technology reads the genetic code of MMR genes letter by letter, identifying any changes from the normal sequence that could impair protein function.^[3]

In addition to finding mutations in the genes themselves, testing also looks for epigenetic changes that can silence gene function without altering the DNA sequence. The most common example is methylation of the MLH1 gene promoter, a chemical modification that prevents the gene from being turned on. This type of silencing typically occurs in sporadic cancers rather than inherited cases, and identifying it helps distinguish between hereditary and non-hereditary causes of mismatch repair deficiency.^[5]

The diagnostic process often follows a stepwise approach. Doctors first perform MSI testing or immunohistochemistry on tumor tissue. If these tests indicate mismatch repair deficiency, genetic counseling and germline genetic testing of blood samples may be recommended to determine if the deficiency is due to an inherited mutation. This staged approach balances thoroughness with efficiency, using simpler tests first to identify which patients need more extensive genetic analysis.

Diagnostics for Clinical Trial Qualification

For individuals considering participation in clinical trials, specific diagnostic criteria determine eligibility. Clinical trials investigating new treatments for cancers with mismatch repair deficiencies typically require documentation of MMR status through standardized testing methods. This ensures that the trial includes patients with the specific molecular characteristics that the treatment is designed to target.^[5]

The most common qualification criterion is demonstration of high microsatellite instability or deficient mismatch repair status in tumor tissue. Trial protocols specify which testing methods are acceptable, typically requiring MSI testing using standardized panels of microsatellite markers or immunohistochemistry showing loss of one or more MMR proteins. The testing must be performed by certified laboratories using validated methods to ensure consistent and reliable results across different study sites.

Some clinical trials specifically focus on tumors with microsatellite instability because these cancers respond differently to certain treatments, particularly immune checkpoint inhibitors. Research has shown that tumors with deficient mismatch repair generate many abnormal proteins called neoantigens because of their high mutation rates. These neoantigens make the cancer more visible to the immune system, which explains why MMR-deficient tumors often respond well to immunotherapy treatments that help the immune system attack cancer cells.^[5]

Documentation requirements for trial enrollment typically include the original pathology report showing MSI-high status or loss of MMR protein expression, along with confirmation that the testing was performed according to established guidelines. Some trials may require retesting of samples at a central laboratory to ensure consistency across all participants. Patients interested in trial participation should discuss with their doctors whether their existing test results meet trial requirements or if additional testing is needed.

Trial protocols may also specify whether patients need germline genetic testing to confirm inherited mutations versus somatic testing that examines only the tumor. Some studies focus exclusively on hereditary cases, while others include both inherited and sporadic MMR-deficient cancers. Understanding these distinctions helps patients and doctors identify the most appropriate trials for each individual’s situation.

Emerging diagnostic technologies continue to refine how mismatch repair status is assessed for clinical trials. Next-generation sequencing, which can analyze multiple genes simultaneously, is increasingly used to comprehensively characterize the genetic landscape of tumors. This broader testing approach not only confirms MMR status but also identifies other genetic changes that might affect treatment response or qualify patients for additional clinical trials targeting different molecular abnormalities.